|
1
|
Chen W and Hu GH: Biomarkers for enhancing
the radiosensitivity of nasopharyngeal carcinoma. Cancer Biol Med.
12:23–32. 2015.PubMed/NCBI
|
|
2
|
Vokes EE, Liebowitz DN and Weichselbaum
RR: Nasopharyngeal carcinoma. Lancet. 350:1087–1091. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Petersson F: Nasopharyngeal carcinoma: A
review. Semin Diagn Pathol. 32:54–73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou X, Xiao X, Huang T, Du C, Wang S, Mo
Y, Ma N, Murata M, Li B, Wen W, et al: Epigenetic inactivation of
follistatin-like 1 mediates tumor immune evasion in nasopharyngeal
carcinoma. Oncotarget. 7:16433–16444. 2016.PubMed/NCBI
|
|
5
|
Aldape K, Zadeh G, Mansouri S,
Reifenberger G and von Deimling A: Glioblastoma: Pathology,
molecular mechanisms and markers. Acta Neuropathol. 129:829–848.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shi W, Bastianutto C, Li A, Perez-Ordonez
B, Ng R, Chow KY, Zhang W, Jurisica I, Lo KW, Bayley A, et al:
Multiple dysregulated pathways in nasopharyngeal carcinoma revealed
by gene expression profiling. Int J Cancer. 119:2467–2475. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Altun M, Fandi A, Dupuis O, Cvitkovic E,
Krajina Z and Eschwege F: Undifferentiated nasopharyngeal cancer
(UCNT): Current diagnostic and therapeutic aspects. Int J Radiat
Oncol Biol Phys. 32:859–877. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tan WL, Tan EH, Lim DW, Ng QS, Tan DS,
Jain A and Ang MK: Advances in systemic treatment for
nasopharyngeal carcinoma. Chin Clin Oncol. 5:212016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parkin DM and Muir CS: Cancer incidence in
five continents. Comparability and quality of data. IARC Sci Publ.
120:45–173. 1992.
|
|
10
|
Lee AW, Sze WM, Au JS, Leung SF, Leung TW,
Chua DT, Zee BC, Law SC, Teo PM, Tung SY, et al: Treatment results
for nasopharyngeal carcinoma in the modern era: The Hong Kong
experience. Int J Radiat Oncol Biol Phys. 61:1107–1116. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cai X, Liu Y, Yang W, Xia Y, Yang C, Yang
S and Liu X: Long noncoding RNA MALAT1 as a potential therapeutic
target in osteosarcoma. J Orthop Res. 34:932–941. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao KT and Lian D: Long non-coding RNA
MALAT1 is an independent prognostic factor of osteosarcoma. Eur Rev
Med Pharmacol Sci. 20:3561–3565. 2016.PubMed/NCBI
|
|
13
|
Huo Y, Li Q, Wang X, Jiao X, Zheng J, Li Z
and Pan X: MALAT1 predicts poor survival in osteosarcoma patients
and promotes cell metastasis through associating with EZH2.
Oncotarget. 8:46993–47006. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Q, Pan X, Wang X, Jiao X, Zheng J, Li Z
and Huo Y: Long noncoding RNA MALAT1 promotes cell proliferation
through suppressing miR-205 and promoting SMAD4 expression in
osteosarcoma. Oncotarget. 8:106648–106660. 2017.PubMed/NCBI
|
|
15
|
Fan L, Huang C, Li J, Gao T, Lin Z and Yao
T: Long non-coding RNA urothelial cancer associated 1 regulates
radioresistance via the hexokinase 2/glycolytic pathway in cervical
cancer. Int J Mol Med. 42:2247–2259. 2018.PubMed/NCBI
|
|
16
|
Wu X, Tudoran OM, Calin GA and Ivan M: The
many faces of long noncoding RNAs in cancer. Antioxid Redox Signal.
29:922–935. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang H, Cai Y, Zheng L, Zhang Z, Lin X
and Jiang N: Long noncoding RNA NEAT1 regulate papillary thyroid
cancer progression by modulating miR-129-5p/KLK7 expression. J Cell
Physiol. 233:6638–6648. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martens-Uzunova ES, Bottcher R, Croce CM,
Jenster G, Visakorpi T and Calin GA: Long noncoding RNA in
prostate, bladder, and kidney cancer. Eur Urol. 65:1140–1151. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Zhu M, Sun Y, Li W, Wang Y and Yu
W: Up-regulation of lncRNA CASC2 suppresses cell proliferation and
metastasis of breast cancer via inactivating of the TGF-β signaling
pathway. Oncol Res. Mar 9–2018.(Epub ahead of print). doi:
10.3727/096504018X15199531937158. View Article : Google Scholar
|
|
20
|
Zhao L and Zhang Y: Long noncoding RNA
CASC2 regulates hepatocellular carcinoma cell oncogenesis through
miR-362-5p/Nf-κB axis. J Cell Physiol. 233:6661–6670. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou J, Huang H, Tong S and Huo R:
Overexpression of long non-coding RNA cancer susceptibility 2
inhibits cell invasion and angiogenesis in gastric cancer. Mol Med
Rep. 16:5235–5240. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ba Z, Gu L, Hao S, Wang X, Cheng Z and Nie
G: Downregulation of lncRNA CASC2 facilitates osteosarcoma growth
and invasion through miR-181a. Cell Prolif. 51:e124092018.
View Article : Google Scholar
|
|
23
|
Fan JC, Zeng F, Le YG and Xin L: lncRNA
CASC2 inhibited the viability and induced the apoptosis of
hepatocellular carcinoma cells through regulating miR-24-3p. J Cell
Biochem. 119:6391–6397. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li H, Shi H, Gao M, Ma N and Sun R: Long
non-coding RNA CASC2 improved acute lung injury by regulating
miR-144-3p/AQP1 axis to reduce lung epithelial cell apoptosis. Cell
Biosci. 8:152018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang D, Gao ZM, Han LG, Xu F, Liu K and
Shen Y: Long noncoding RNA CASC2 inhibits metastasis and epithelial
to mesenchymal transition of lung adenocarcinoma via suppressing
SOX4. Eur Rev Med Pharmacol Sci. 21:4584–4590. 2017.PubMed/NCBI
|
|
26
|
Calin GA and Croce CM: Chromosomal
rearrangements and microRNAs: A new cancer link with clinical
implications. J Clin Invest. 117:2059–2066. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liz J and Esteller M: lncRNAs and
microRNAs with a role in cancer development. Biochim Biophys Acta
1859. 169–176. 2016.
|
|
28
|
Yoon JH, Abdelmohsen K and Gorospe M:
Functional interactions among microRNAs and long noncoding RNAs.
Semin Cell Dev Biol. 34:9–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baldinu P, Cossu A, Manca A, Satta MP,
Sini MC, Rozzo C, Dessole S, Cherchi P, Gianfrancesco F, Pintus A,
et al: Identification of a novel candidate gene, CASC2, in a region
of common allelic loss at chromosome 10q26 in human endometrial
cancer. Hum Mutat. 23:318–326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baldinu P, Cossu A, Manca A, Satta MP,
Sini MC, Palomba G, Dessole S, Cherchi P, Mara L, Tanda F and
Palmieri G: CASC2a gene is down-regulated in endometrial cancer.
Anticancer Res. 27:235–243. 2007.PubMed/NCBI
|
|
32
|
Wang KC and Chang HY: Molecular mechanisms
of long noncoding RNAs. Mol Cell. 43:904–914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y,
Chen W, Liu F, Sun W, Li XF, et al: Exosome-transmitted lncARSR
promotes sunitinib resistance in renal cancer by acting as a
competing endogenous RNA. Cancer Cell. 29:653–668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao W, Lin S, Cheng C, Zhu A, Hu Y, Shi Z,
Zhang X and Hong Z: Long non-coding RNA CASC2 regulates Sprouty2
via functioning as a competing endogenous RNA for miR-183 to
modulate the sensitivity of prostate cancer cells to docetaxel.
Arch Biochem Biophys. 2018 Jan 23;(pii): S0003-9861(17)30840-8.
doi: 10.1016/j.abb.2018.01.013. PubMed/NCBI
|
|
35
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 9:8522017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Q, Yu W, Zhu S, Cheng K, Xu H, Lv Y,
Long X, Ma L, Huang J, Sun S and Wang K: Long noncoding RNA GAS5
regulates the proliferation, migration, and invasion of glioma
cells by negatively regulating miR-18a-5p. J Cell Physiol.
234:775–768. 2018.
|
|
37
|
Zhang N, Zhang H, Liu Y, Su P, Zhang J,
Wang X, Sun M, Chen B, Zhao W, Wang L, et al: SREBP1, targeted by
miR-18a-5p, modulates epithelial-mesenchymal transition in breast
cancer via forming a co-repressor complex with snail and HDAC1/2.
Cell Death Differ. Jul 9–2018.(Epub ahead of print). doi:
10.1038/s41418-018-0158-8.
|
|
38
|
Zhou L, Li Z, Pan X, Lai Y, Quan J, Zhao
L, Xu J, Xu W, Guan X, Li H, et al: Identification of miR-18a-5p as
an oncogene and prognostic biomarker in RCC. Am J Transl Res.
10:1874–1886. 2018.PubMed/NCBI
|
|
39
|
Liang C, Zhang X, Wang HM, Liu XM, Zhang
XJ, Zheng B, Qian GR and Ma ZL: MicroRNA-18a-5p functions as an
oncogene by directly targeting IRF2 in lung cancer. Cell Death Dis.
8:e27642017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schaeper U, Subramanian T, Lim L, Boyd JM
and Chinnadurai G: Interaction between a cellular protein that
binds to the C-terminal region of adenovirus E1A (CtBP) and a novel
cellular protein is disrupted by E1A through a conserved PLDLS
motif. J Biol Chem. 273:8549–8552. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Koipally J and Georgopoulos K: Ikaros-CtIP
interactions do not require C-terminal binding protein and
participate in a deacetylase-independent mode of repression. J Biol
Chem. 277:23143–23149. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sum EY, Peng B, Yu X, Chen J, Byrne J,
Lindeman GJ and Visvader JE: The LIM domain protein LMO4 interacts
with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits
BRCA1 activity. J Biol Chem. 277:7849–7856. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ikenoue T, Togo G, Nagai K, Ijichi H, Kato
J, Yamaji Y, Okamoto M, Kato N, Kawabe T, Tanaka A, et al:
Frameshift mutations at mononucleotide repeats in RAD50
recombinational DNA repair gene in colorectal cancers with
microsatellite instability. Jpn J Cancer Res. 92:587–591. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bilbao C, Ramirez R, Rodriguez G, Falcón
O, León L, Díaz-Chico N, Perucho M and Díaz-Chico JC: Double strand
break repair components are frequent targets of microsatellite
instability in endometrial cancer. Eur J Cancer. 46:2821–2827.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fusco C, Reymond A and Zervos AS:
Molecular cloning and characterization of a novel
retinoblastoma-binding protein. Genomics. 51:351–358. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yamaguchi N, Osaki M, Onuma K, Yumioka T,
Iwamoto H, Sejima T, Kugoh H, Takenaka A and Okada F:
Identification of microRNAs involved in resistance to sunitinib in
renal cell carcinoma cells. Anticancer Res. 37:2985–2992.
2017.PubMed/NCBI
|
